Multicenter Observational Study of Fulvestrant 500 mg in Postmenopausal Japanese Women with Estrogen Receptor-Positive Advanced or Recurrent Breast Cancer after Prior Endocrine Treatment (SBCCSG29 Study)-Reference-Cited by-同舟云学术

Multicenter Observational Study of Fulvestrant 500 mg in Postmenopausal Japanese Women with Estrogen Receptor-Positive Advanced or Recurrent Breast Cancer after Prior Endocrine Treatment (SBCCSG29 Study)

Published:2019-06-26 Issue:3 Volume:86 Page:165-171
ISSN:1345-4676
Container-title:Journal of Nippon Medical School
language:en
Short-container-title:J Nippon Med Sch

Author:

Kimizuka Kei¹,Inoue Kenichi²,E. Nagai Shigenori²,Saito Tsuyoshi³,Nakano Satoko⁴,Futsuhara Kazushige⁵,Yamada Hirofumi⁶,Kaneko Shiori⁷,Sakurai Takashi⁸,Hata Satoshi⁹,Kurosumi Masafumi¹⁰

Affiliation:

1. Department of Breast Surgery, Kasukabe Medical Center

2. Division of Breast Oncology, Saitama Cancer Center

3. Department of Breast Surgery, Japanese Red Cross Saitama Hospital

4. Department of Surgery, Kawaguchi Municipal Medical Center

5. Department of Surgery, Jichi Medical University, Saitama Medical Center

6. Department of Breast Oncology, Sekishindo Hospital

7. Department of Surgery, Saitama Cooperative Hospital

8. Department of Surgery, Saitama Medical Center

9. Department of Breast Surgery, Mitsui Hospital

10. Kameda Kyobashi Clinic, Division of Pathology

Publisher

Medical Association of Nippon Medical School

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/jnms/86/3/86_JNMS.2019_86-305/_pdf

Reference10 articles.

1. 1. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A: Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: Results of a North American Trial. J Clin Oncol 2002; 20: 3386-3395.

2. 2. Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M: Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor-Positive, Advanced Breast Cancer: Results From EFECT. J Clin Oncol 2008; 26: 1664-1670.

3. 3. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Garnett S, Lindemann JP, Sapunar F, Martin M: Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer. J Clin Oncol 2010; 28: 4594-4600.

4. 4. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Malorni L, Garnett S, Rukazenkov Y, Martin M: Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst 2014; 106: 337.

5. 5. Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, Fallowfield L, Fowble B, Ingle JN, Jahanzeb M, Johnston SRD, Korde LA, Khatcheressian JL, Mehta RS, Muss HB, Burstein HJ: Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol 2016; 34: 3069-3103.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fulvestrant;Reactions Weekly;2019-11